Literature DB >> 27038187

Relative expression and correlation of tumor necrosis factor-α, interferon-γ, and interleukin-17 in the rheumatoid synovium.

Arata Nakajima1,2, Yasuchika Aoki3,4, Masato Sonobe5, Fusako Watanabe5, Hiroshi Takahashi5, Masahiko Saito5, Koichi Nakagawa5.   

Abstract

Although tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ), and interleukin-17 (IL-17) play important roles in RA, their relative expression and possible correlation in synovial tissues are not well understood. In this study, mRNA expression levels of IFN-γ, IL-17, and TNF-α were investigated in individual patients with RA and the correlations between pairs of these three pro-inflammatory cytokines were analyzed. Synovial tissues were obtained during arthroplasties from 24 joints of 24 RA patients. After harvesting synovial tissues, total RNA was isolated then quantitative real-time polymerase chain reaction (qRT-PCR) for IFN-γ, IL-17, and TNF-α was performed. Correlation of expression levels between them was also analyzed. Expression levels of TNF-α, IFN-γ, and IL-17 in patients receiving TNF inhibitors (TNFi) and those treated with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) alone were also compared between groups. Based on relative expression levels of the three pro-inflammatory cytokines, patients were classified into three major types; an IFN-γ plus TNF-α-dominant type, an IL-17-dominant type, and the other type. TNF-α expression levels were correlated with IFN-γ. In addition, there was a negative correlation between TNF-α and IL-17, and IFN-γ and IL-17. Median relative expression levels of TNF-α have no significant difference between the TNFi and the csDMARDs groups. In the rheumatoid synovial tissues, expression levels of TNF-α were modulated in parallel with IFN-γ, and TNF-α and IL-17, or IFN-γ and IL-17 did not co-express at high levels. This characteristic expression pattern of the three pro-inflammatory cytokines may be clinically useful information in the current cytokine-targeted treatment with biological DMARDs for RA.

Entities:  

Keywords:  Interferon-γ (IFN-γ); Interleukin-17 (IL-17); Rheumatoid arthritis; Synovium; Tumor necrosis factor-α (TNF-α)

Mesh:

Substances:

Year:  2016        PMID: 27038187     DOI: 10.1007/s10067-016-3249-2

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis.

Authors:  S Kotake; N Udagawa; N Takahashi; K Matsuzaki; K Itoh; S Ishiyama; S Saito; K Inoue; N Kamatani; M T Gillespie; T J Martin; T Suda
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

Review 2.  Reappraising metalloproteinases in rheumatoid arthritis and osteoarthritis: destruction or repair?

Authors:  Gillian Murphy; Hideaki Nagase
Journal:  Nat Clin Pract Rheumatol       Date:  2008-03

3.  Anti-tumor necrosis factor (TNF) therapy in rheumatoid arthritis: correlation of TNF-alpha serum level with clinical response and benefit from changing dose or frequency of infliximab infusions.

Authors:  A F Edrees; S N Misra; N I Abdou
Journal:  Clin Exp Rheumatol       Date:  2005 Jul-Aug       Impact factor: 4.473

4.  Application of a new immunohistology scoring system (IH score): analysis of TNF-α in synovium related to disease activity score in infliximab-treated patients with rheumatoid arthritis.

Authors:  Katsuaki Kanbe; Ryota Hara; Junji Chiba; Yasuo Inoue; Masashi Taguchi; Yasuhito Tanaka
Journal:  Mod Rheumatol       Date:  2014-03-26       Impact factor: 3.023

5.  T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma.

Authors:  H Takayanagi; K Ogasawara; S Hida; T Chiba; S Murata; K Sato; A Takaoka; T Yokochi; H Oda; K Tanaka; K Nakamura; T Taniguchi
Journal:  Nature       Date:  2000-11-30       Impact factor: 49.962

6.  Both etanercept and infliximab can elevate tumor necrosis factor (TNF)-alpha and be the cause of treatment related new onset disease: the need to measure circulating TNF-alpha.

Authors:  Richard E Kast; Eric L Altschuler
Journal:  J Rheumatol       Date:  2008-08       Impact factor: 4.666

7.  A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.

Authors:  Mark C Genovese; Maria Greenwald; Chul-Soo Cho; Alberto Berman; Ling Jin; Gregory S Cameron; Olivier Benichou; Li Xie; Daniel Braun; Pierre-Yves Berclaz; Subhashis Banerjee
Journal:  Arthritis Rheumatol       Date:  2014-07       Impact factor: 10.995

8.  Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway.

Authors:  Saba Alzabin; Sonya M Abraham; Taher E Taher; Andrew Palfreeman; Dobrina Hull; Kay McNamee; Ali Jawad; Ejaz Pathan; Anne Kinderlerer; Peter C Taylor; Richard Williams; Rizgar Mageed
Journal:  Ann Rheum Dis       Date:  2012-05-01       Impact factor: 19.103

9.  Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction.

Authors:  Kojiro Sato; Ayako Suematsu; Kazuo Okamoto; Akira Yamaguchi; Yasuyuki Morishita; Yuho Kadono; Sakae Tanaka; Tatsuhiko Kodama; Shizuo Akira; Yoichiro Iwakura; Daniel J Cua; Hiroshi Takayanagi
Journal:  J Exp Med       Date:  2006-11-06       Impact factor: 14.307

Review 10.  Rheumatoid arthritis pathophysiology: update on emerging cytokine and cytokine-associated cell targets.

Authors:  Daniel E Furst; Paul Emery
Journal:  Rheumatology (Oxford)       Date:  2014-01-08       Impact factor: 7.580

View more
  3 in total

1.  Effect of Interferon-γ Polymorphisms on Ankylosing Spondylitis: A Case-Control Study.

Authors:  Haitao Xu; Bo Li
Journal:  Med Sci Monit       Date:  2017-08-26

Review 2.  Bimodal Function of Anti-TNF Treatment: Shall We Be Concerned about Anti-TNF Treatment in Patients with Rheumatoid Arthritis and Heart Failure?

Authors:  Przemyslaw J Kotyla
Journal:  Int J Mol Sci       Date:  2018-06-12       Impact factor: 5.923

3.  Micheliolide alleviates ankylosing spondylitis (AS) by suppressing the activation of the NLRP3 inflammasome and maintaining the balance of Th1/Th2 via regulating the NF-κB signaling pathway.

Authors:  Zhong-Gu Tian; Miaomiao Yao; Jie Chen
Journal:  Ann Transl Med       Date:  2020-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.